Evolving molecularly targeted therapies for advanced-stage thyroid cancers

Keith C. Bible, Mabel Ryder

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Increased understanding of disease-specific molecular targets of therapy has led to the regulatory approval of two drugs (vandetanib and cabozantinib) for the treatment of medullary thyroid cancer (MTC), and two agents (sorafenib and lenvatinib) for the treatment of radioactive- iodine refractory differentiated thyroid cancer (DTC) in both the USA and in the EU. The effects of these and other therapies on overall survival and quality of life among patients with thyroid cancer, however, remain to be more-clearly defined. When applied early in the disease course, intensive multimodality therapy seems to improve the survival outcomes of patients with anaplastic thyroid cancer (ATC), but salvage therapies for ATC are of uncertain benefit. Additional innovative, rationally designed therapeutic strategies are under active development both for patients with DTC and for patients with ATC, with multiple phase II and phase III randomized clinical trials currently ongoing. Continued effort is being made to identify further signalling pathways with potential therapeutic relevance in thyroid cancers, as well as to elaborate on the complex interactions between signalling pathways, with the intention of translating these discoveries into effective and personalized therapies. Herein, we summarize the progress made in molecular medicine for advanced-stage thyroid cancers of different histotypes, analyse how these developments have altered — and might further refine — patient care, and identify open questions for future research.

Original languageEnglish (US)
JournalNature Reviews Clinical Oncology
DOIs
StateAccepted/In press - Mar 1 2016

Fingerprint

Thyroid Neoplasms
Therapeutics
Molecular Medicine
Drug Approval
Salvage Therapy
Phase III Clinical Trials
Survival
Iodine
Patient Care
Randomized Controlled Trials
Quality of Life
Anaplastic Thyroid Carcinoma

ASJC Scopus subject areas

  • Oncology

Cite this

Evolving molecularly targeted therapies for advanced-stage thyroid cancers. / Bible, Keith C.; Ryder, Mabel.

In: Nature Reviews Clinical Oncology, 01.03.2016.

Research output: Contribution to journalArticle

@article{2cacd6318a394875b5b5d7a6ca9ca330,
title = "Evolving molecularly targeted therapies for advanced-stage thyroid cancers",
abstract = "Increased understanding of disease-specific molecular targets of therapy has led to the regulatory approval of two drugs (vandetanib and cabozantinib) for the treatment of medullary thyroid cancer (MTC), and two agents (sorafenib and lenvatinib) for the treatment of radioactive- iodine refractory differentiated thyroid cancer (DTC) in both the USA and in the EU. The effects of these and other therapies on overall survival and quality of life among patients with thyroid cancer, however, remain to be more-clearly defined. When applied early in the disease course, intensive multimodality therapy seems to improve the survival outcomes of patients with anaplastic thyroid cancer (ATC), but salvage therapies for ATC are of uncertain benefit. Additional innovative, rationally designed therapeutic strategies are under active development both for patients with DTC and for patients with ATC, with multiple phase II and phase III randomized clinical trials currently ongoing. Continued effort is being made to identify further signalling pathways with potential therapeutic relevance in thyroid cancers, as well as to elaborate on the complex interactions between signalling pathways, with the intention of translating these discoveries into effective and personalized therapies. Herein, we summarize the progress made in molecular medicine for advanced-stage thyroid cancers of different histotypes, analyse how these developments have altered — and might further refine — patient care, and identify open questions for future research.",
author = "Bible, {Keith C.} and Mabel Ryder",
year = "2016",
month = "3",
day = "1",
doi = "10.1038/nrclinonc.2016.19",
language = "English (US)",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Evolving molecularly targeted therapies for advanced-stage thyroid cancers

AU - Bible, Keith C.

AU - Ryder, Mabel

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Increased understanding of disease-specific molecular targets of therapy has led to the regulatory approval of two drugs (vandetanib and cabozantinib) for the treatment of medullary thyroid cancer (MTC), and two agents (sorafenib and lenvatinib) for the treatment of radioactive- iodine refractory differentiated thyroid cancer (DTC) in both the USA and in the EU. The effects of these and other therapies on overall survival and quality of life among patients with thyroid cancer, however, remain to be more-clearly defined. When applied early in the disease course, intensive multimodality therapy seems to improve the survival outcomes of patients with anaplastic thyroid cancer (ATC), but salvage therapies for ATC are of uncertain benefit. Additional innovative, rationally designed therapeutic strategies are under active development both for patients with DTC and for patients with ATC, with multiple phase II and phase III randomized clinical trials currently ongoing. Continued effort is being made to identify further signalling pathways with potential therapeutic relevance in thyroid cancers, as well as to elaborate on the complex interactions between signalling pathways, with the intention of translating these discoveries into effective and personalized therapies. Herein, we summarize the progress made in molecular medicine for advanced-stage thyroid cancers of different histotypes, analyse how these developments have altered — and might further refine — patient care, and identify open questions for future research.

AB - Increased understanding of disease-specific molecular targets of therapy has led to the regulatory approval of two drugs (vandetanib and cabozantinib) for the treatment of medullary thyroid cancer (MTC), and two agents (sorafenib and lenvatinib) for the treatment of radioactive- iodine refractory differentiated thyroid cancer (DTC) in both the USA and in the EU. The effects of these and other therapies on overall survival and quality of life among patients with thyroid cancer, however, remain to be more-clearly defined. When applied early in the disease course, intensive multimodality therapy seems to improve the survival outcomes of patients with anaplastic thyroid cancer (ATC), but salvage therapies for ATC are of uncertain benefit. Additional innovative, rationally designed therapeutic strategies are under active development both for patients with DTC and for patients with ATC, with multiple phase II and phase III randomized clinical trials currently ongoing. Continued effort is being made to identify further signalling pathways with potential therapeutic relevance in thyroid cancers, as well as to elaborate on the complex interactions between signalling pathways, with the intention of translating these discoveries into effective and personalized therapies. Herein, we summarize the progress made in molecular medicine for advanced-stage thyroid cancers of different histotypes, analyse how these developments have altered — and might further refine — patient care, and identify open questions for future research.

UR - http://www.scopus.com/inward/record.url?scp=84959525978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959525978&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2016.19

DO - 10.1038/nrclinonc.2016.19

M3 - Article

C2 - 26925962

AN - SCOPUS:84959525978

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

ER -